Confidence Region Approach for Assessing Bioequivalence and Biosimilarity Accounting for Heterogeneity of Variability
For approval of generic drugs, the FDA requires that evidence of bioequivalence in average bioequivalence in terms of drug absorption be provided through the conduct of a bioequivalence study. A test product is said to be average bioequivalent to a reference (innovative) product if the 90% confidenc...
Saved in:
Main Authors: | Jianghao Li, Shein-Chung Chow |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Journal of Probability and Statistics |
Online Access: | http://dx.doi.org/10.1155/2015/298647 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pimobendan oral solution is bioequivalent to pimobendan chewable tablets in beagle dogs
by: Olaf Kuhlmann, et al.
Published: (2025-01-01) -
Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in Rats
by: Hyukjun Cho, et al.
Published: (2025-01-01) -
Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
by: Mohammed Alqahtani, et al.
Published: (2024-11-01) -
Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Vardenafil and Its Application of Bioequivalence
by: Kok Zheng Gan, et al.
Published: (2021-01-01) -
Assessment of spatial heterogeneity of employment in Russian regions
by: R. I. Vasilyeva, et al.
Published: (2023-12-01)